Meningococcal (Meningitis) Vaccines
Meningococcal disease is a severe bacterial infection caused by Neisseria meningitidis. As a result, it leads to meningitis (inflammation of the brain and spinal cord linings) or meningococcemia (bloodstream infection).
Furthermore, it can progress rapidly—sometimes within hours. Therefore, it carries a high risk of death or long-term disability if untreated.
Vaccination is the most effective way to prevent meningococcal disease. Specifically, it is especially important for adolescents, healthcare workers, military and dormitory residents, overseas workers, and travelers to countries where meningococcal disease is common or required for entry (such as Saudi Arabia for Hajj pilgrims).
Additionally, Affinity Vaccines offers Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) from trusted global manufacturers: Menactra®, MenQuadfi®, and Nimenrix®.
A. Menactra® (Sanofi Pasteur)
1. Menactra® (Sanofi Pasteur)
Formulation:
Quadrivalent conjugate vaccine containing polysaccharides from Neisseria meningitidis serogroups A, C, Y, and W-135. Specifically, each is conjugated to diphtheria toxoid protein carrier.
Packaging:
Single-dose vial, 0.5 mL per dose (liquid formulation). Therefore, no reconstitution needed.
Dosage and Administration:
- Children (≥ 9 months–23 months): Two doses, 0.5 mL each, at least 3 months apart.
- Adolescents and adults (2–55 years): One 0.5 mL intramuscular injection.
- Additionally, booster every 5 years for continued protection or for travelers to common outbreak areas.
Indications:
Active protection against meningococcal disease caused by serogroups A, C, Y, and W-135. Specifically, it is ideal for adolescents, military personnel, healthcare workers, and travelers to meningitis-common regions (e.g., Hajj pilgrims).
Contraindications:
- Allergic reaction to any vaccine component (e.g., diphtheria toxoid).
- Also, defer vaccination in acute illness with fever.
Storage / Cold-Chain Requirement:
- Store between +2°C and +8°C.
- Do not freeze.
- Additionally, protect from light.
Manufacturer:
Sanofi Pasteur S.A., France
B. MenQuadfi® (Sanofi Pasteur)
2. MenQuadfi® (Sanofi Pasteur)
Formulation:
Quadrivalent meningococcal conjugate vaccine containing polysaccharides of N. meningitidis serogroups A, C, Y, and W. Specifically, these are conjugated to tetanus toxoid carrier protein.
Packaging:
Single-dose vial, 0.5 mL per dose (ready-to-use liquid formulation).
Dosage and Administration:
- Individuals ≥ 12 months: One 0.5 mL intramuscular dose.
- Additionally, booster every 5 years for those at ongoing risk.
Indications:
Prevention of invasive meningococcal disease caused by N. meningitidis serogroups A, C, Y, and W. Specifically, it is suitable for children (≥ 1 year), adolescents, and adults up to age 55.
Contraindications:
- Allergic reaction to tetanus toxoid or any vaccine ingredient.
- Also, delay vaccination during acute illness.
Storage / Cold-Chain Requirement:
- Maintain +2°C to +8°C.
- Do not freeze.
- Additionally, protect from light.
Manufacturer:
Sanofi Pasteur S.A., France
C. Nimenrix® (GlaxoSmithKline – GSK)
3. Menveo® (GSK)
Formulation:
Quadrivalent conjugate vaccine containing polysaccharides of N. meningitidis serogroups A, C, W-135, and Y. Specifically, each is conjugated to tetanus toxoid carrier protein. Additionally, it comes as lyophilized powder for reconstitution.
Packaging:
Single-dose vial (lyophilized vaccine) with pre-filled syringe of diluent. After reconstitution, it provides 0.5 mL dose.
Dosage and Administration:
- Children (≥ 6 weeks to 12 months): Two doses, 0.5 mL each, 2 months apart.
- Adolescents and adults (≥ 12 months): Single 0.5 mL intramuscular dose.
- Furthermore, booster every 5 years if continued risk exists.
Indications:
Active protection against invasive meningococcal disease caused by N. meningitidis serogroups A, C, W-135, and Y. Specifically, it is suitable for both pediatric and adult use. Moreover, it is commonly accepted for international travel vaccine requirements.
Contraindications:
- Allergic reaction to any component, including tetanus toxoid.
- Also, defer during moderate or severe acute illness.
Storage / Cold-Chain Requirement:
- Store between +2°C and +8°C.
- Do not freeze.
- Additionally, protect from light.
- Importantly, use immediately after reconstitution.
Manufacturer:
GlaxoSmithKline Biologicals S.A., Belgium
Corporate Vaccination Recommendations
Target Group | Recommended Vaccine | Notes |
Adults and employees traveling abroad (e.g., Hajj, Africa, Middle East) | Menactra® / MenQuadfi® / Nimenrix® | Required for Hajj pilgrims and international travelers. |
Healthcare, military, and field workers | MenQuadfi® / Nimenrix® | Protects against invasive meningococcal disease in high-risk exposure settings. |
Students or employees in dormitories | Menactra® / MenQuadfi® | Reduces transmission in close-contact environments. |
Pediatric and dependent vaccination (≥ 1 year old) | Nimenrix® | Safe and immunogenic in children as young as 6 weeks old. |
Affinity Vaccines Recommendation:
For broad coverage and flexible age indication, MenQuadfi® or Nimenrix® are preferred choices for both adult and dependent vaccination programs.
Cold-Chain and Safety Assurance
All meningococcal vaccines are handled within +2 °C to +8 °C and administered by licensed medical professionals in accordance with DOH and FDA standards.
Each corporate vaccination program includes batch tracking, cold-chain validation, and post-vaccination monitoring for maximum safety and efficacy.
Protect Your People. Protect Your Business. Strengthen Your Organization.
Meningococcal disease can strike quickly — but vaccination provides lasting, reliable protection.
Affinity Vaccines offers corporate meningitis immunization programs using Menactra®, MenQuadfi®, and Nimenrix®, ensuring safe and compliant vaccination for employees and dependents.
📩 Request for a Corporate Vaccination Proposal
Email: vaccines@affinity.com.ph